MARKET INSIGHTS
Global (S)-3-Amino-3-(4-bromophenyl)propionic acid market size was valued at USD 18.6 million in 2025. The market is projected to rise from USD 20.1 million in 2026 to USD 38.4 million by 2034, reflecting a CAGR of 8.4% over the forecast period.
(S)-3-Amino-3-(4-bromophenyl)propionic acid is a chiral beta‑amino acid derivative featuring a bromine substituent at the para position of the phenyl ring. Its defined stereochemistry renders it indispensable in the synthesis of peptidomimetics, protease inhibitors and other biologically active molecules, positioning it as a cornerstone in asymmetric synthesis and medicinal chemistry.
The market is expanding steadily, driven by rising demand from the pharmaceutical and biotechnology sectors for complex drug candidates and research intermediates. The broader adoption of chiral chemistry in drug development, coupled with increasing investment in fine chemical manufacturing, continues to support this upward trajectory. Leading suppliers—Sigma‑Aldrich (Merck KGaA), TCI Chemicals and Combi‑Blocks—provide high‑purity product lines for both research and commercial‑scale applications.
(S)-3-Amino-3-(4-bromophenyl)propionic acid Market – View in Detailed Research Report
Top 10 Companies in the (S)-3-Amino-3-(4-bromophenyl)propionic Acid Market
10. Apollo Scientific Ltd. (UK)
Headquarters: London, United Kingdom
Key Offering: High‑purity chiral intermediates for peptide and small‑molecule drug discovery
Apollo Scientific leverages its long‑standing expertise in fine‑chemical synthesis to supply enantiomerically pure (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid to leading pharmaceutical and biotechnology firms. Its streamlined production pipeline delivers consistent 99.5% ee grades, meeting the rigorous demands of late‑stage synthesis and API development.
Sustainability & Growth Initiatives: Investment in continuous‑flow reactors and renewable‑energy‑powered facilities to reduce carbon footprint and enhance process efficiency.
- Deployment of modular flow‑chemistry units for rapid scale‑up
- Partnerships with contract research organizations to expand custom synthesis services
- Commitment to ISO 14001 certification across all manufacturing sites
9. Tokyo Chemical Industry Co., Ltd. (Japan)
Headquarters: Tokyo, Japan
Key Offering: Specialty chiral building blocks for peptide therapeutics
TCI’s advanced chiral resolution capabilities enable it to supply (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid with exceptional purity, supporting the development of oncology and neurology agents. Its integrated supply chain ensures rapid delivery to global R&D hubs.
Sustainability & Growth Initiatives: Focus on green chemistry through biocatalytic routes and waste minimization programs.
- Biocatalytic synthesis of chiral intermediates with >95% yield
- Reduction of hazardous waste by 30% via process optimization
- Collaboration with universities to develop next‑generation asymmetric catalysts
8. Biosynth AG (Switzerland)
Headquarters: Basel, Switzerland
Key Offering: High‑purity chiral amino acids for advanced medicinal chemistry
Biosynth’s state‑of‑the‑art asymmetric hydrogenation platform delivers (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid at scale, supporting the synthesis of complex peptide‑like scaffolds. Its robust quality system aligns with EMA requirements, ensuring seamless regulatory compliance.
Sustainability & Growth Initiatives: Commitment to circular chemistry and renewable feedstock utilization.
- Implementation of solvent‑free reaction protocols
- Use of bio‑derived feedstocks for brominated intermediates
- Participation in EU circular economy projects
7. Enamine LLC (Ukraine)
Headquarters: Kyiv, Ukraine
Key Offering: Custom synthesis of chiral intermediates for academic and industrial research
Enamine’s flexible synthesis routes enable rapid delivery of (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid to niche markets, including PROTACs and macrocyclic peptides. Its emphasis on high enantiomeric excess (>99% ee) distinguishes it in a crowded fine‑chemical landscape.
Sustainability & Growth Initiatives: Adoption of continuous‑flow technology and energy‑efficient reactors.
- Integration of micro‑reactor systems for scale‑up
- Energy recovery from exothermic processes
- Collaboration with global CDMOs for joint venture projects
6. Finetech Industry Limited (China)
Headquarters: Shanghai, China
Key Offering: Bulk production of high‑purity chiral amino acids
Finetech’s large‑scale asymmetric hydrogenation facilities supply (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid to the burgeoning Chinese pharmaceutical sector, ensuring consistent supply for domestic API development.
Sustainability & Growth Initiatives: Focus on process intensification and waste minimization.
- Implementation of closed‑loop water recycling systems
- Adoption of greener solvents for downstream purification
- Partnerships with local universities for catalyst research
5. PharmaBlock Sciences (Nanjing), Inc. (China)
Headquarters: Nanjing, China
Key Offering: Specialty chiral intermediates for protease inhibitor development
PharmaBlock’s proprietary chiral resolution techniques deliver (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid with >99.5% ee, supporting the synthesis of next‑generation protease inhibitors for oncology and viral diseases.
Sustainability & Growth Initiatives: Investment in green chemistry and digital supply chain management.
- Digital tracking of raw‑material provenance
- Implementation of renewable energy sources at production sites
- Collaboration with CDMOs to expand custom synthesis services
4. Senova Technology Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: High‑purity chiral building blocks for peptide‑based therapeutics
Senova’s scalable synthesis platform ensures rapid turnaround for (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid, meeting the needs of both domestic and international R&D labs.
Sustainability & Growth Initiatives: Focus on process optimization and renewable feedstock sourcing.
- Optimization of catalytic cycles to reduce reagent consumption
- Use of renewable raw materials for brominated intermediates
- Integration of AI‑driven process control systems
3. Shanghai Trustin Chemical Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: Premium chiral intermediates for small‑molecule drug development
Trustin’s advanced chiral resolution techniques deliver (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid with exceptional purity, supporting the synthesis of complex therapeutic candidates.
Sustainability & Growth Initiatives: Commitment to green chemistry and energy efficiency.
- Implementation of energy‑efficient distillation units
- Reduction of hazardous waste through process redesign
- Partnerships with academic institutions for catalyst development
2. Ningbo Inno Pharmchem Co., Ltd. (China)
Headquarters: Ningbo, China
Key Offering: Custom synthesis of chiral intermediates for pharmaceutical R&D
Inno Pharmchem’s flexible manufacturing platform supports rapid scale‑up of (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid, catering to the evolving needs of contract research organizations and large pharma.
Sustainability & Growth Initiatives: Investment in continuous‑flow chemistry and renewable energy.
- Deployment of modular flow‑chemistry units for scalable production
- Adoption of renewable electricity for plant operations
- Collaboration with CDMOs to broaden custom synthesis capabilities
1. Capot Chemical Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: High‑purity (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid for API synthesis and research
Capot’s integrated asymmetric hydrogenation platform delivers the compound with >99.8% ee, positioning it as a preferred supplier for pharmaceutical manufacturers seeking reliable, high‑quality intermediates.
Sustainability & Growth Initiatives: Focus on process intensification and circular chemistry.
- Implementation of solvent‑free reaction protocols
- Recovery and reuse of brominated by‑products
- Strategic alliances with global CDMOs for expanded market reach
Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307829/aminopropionic-acid-market
Get Full Report: https://www.24chemicalresearch.com/reports/307829/aminopropionic-acid-market
Future Outlook: Global Demand for Chiral Intermediates Continues to Accelerate
The expanding pipeline of peptide‑based therapeutics and the growing emphasis on stereoselective drug design keep the demand for (S)-3‑Amino‑3‑(4‑bromophenyl)propionic acid high. Regulatory frameworks that prioritize chiral purity and the adoption of green chemistry in synthesis processes are expected to sustain market momentum through 2034.
Key Trends Shaping the Market
- Continued investment in biocatalytic and continuous‑flow synthesis to improve yield and reduce waste.
- Growth of custom synthesis services driven by contract research organizations and CDMOs.
- Emergence of PROTACs and macrocyclic peptides, creating new application avenues.
- Expansion of production capacity in Asia‑Pacific, driven by cost advantages and supportive regulatory environments.
- Increasing focus on sustainability, including renewable feedstock sourcing and energy‑efficient manufacturing.
- Top 10 Companies in the Giant Magnetostrictive Materials Market (2026): Market Leaders Powering Advanced Automation - October 6, 2026
- Top 10 Companies in the Masterbatch Market (2034): Market Leaders Powering Global Innovation - October 6, 2026
- Top 10 Companies in the Global Single Crystal Dense Material Market (2026): Market Leaders Powering Advanced Materials - October 6, 2026